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Abstract 
Case report on acute myeloid leukemia with 
t(12;13)(p13;q12) and ETV6 involvement; Case 
report and review of literature. 
Clinics 
Age and sex 
61 years old male patient. 
Previous history 
No preleukemia; no previous malignancy; no inborn 
condition of note  
Organomegaly 
No hepatomegaly , no splenomegaly , no enlarged 
lymph nodes , no central nervous system 
involvement  
Blood 
WBC: 5.4X 109/l 
HB: 6.8g/dl 
Platelets: 56X 109/l 
Blasts: 22% myeloblasts 
Bone marrow: 60% cellularity; 30% intermediate-
to-large size blasts with open chromatin and no Auer 
rods; decreased trilineage hematopoiesis; significant 




Bone marrow and peripheral blood smear findings 
were both morphologically consistent with acute 
myeloid leukemia (AML). 
Immunophenotype 
Flow cytometry of the bone marrow sample showed 
a myeloblast population representing 33% of the 
cells that were positive for CD34, CD33, CD117, 
CD11b, CD11c, CD13, and cytoplasmic MPO. 





Acute Myeloid Leukemia, NOS (WHO, 2016). 
Survival 
Date of diagnosis 
12-2017 
Treatment 
The patient began induction chemotherapy regimen 
on 1/7/2018 consisting of 7 days of daily cytarabine 
infusion and 3 days of daily daunorubicin. On 
2/15/2018 he was treated for refractory AML with a 
five-day course of mitoxantrone, etoposide, and 
cytarabine. 
Complete remission: no   
Treatment related death: no   
Relapse: Remission never achieved. 
Status Alive 
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Figure 1. G-banded karyotype one month after induction chemotherapy showing t(12;13), trisomy chromosomes 8 and 21 
 





Sample Bone marrow aspirate. 
Culture time 24h 
Banding GTG band level: 350-400 
Results 
47,XY,t(12;13)(p13;q12),+21 [20] 
Karyotype at Relapse 




48,XY,+8, t(12;13)(p13;q12),+21[5] [Figure 1] 
Other molecular cytogenetics technics 
Fluorescence in situ hybridization (FISH) using 
ETV6 LSI break apart probe (Abbott Molecular, Des 
Plaines, IL USA). 
Other molecular cytogenetics results 
Fluorescence in situ hybridization (FISH) with 
EVT6 probe revealed one fusion signal and split 
signal corresponding to the t(12;13)(p13;q12) 
however, the partner gene on chromosome 13q12 
was not tested [Figures 2]. 
Other Molecular Studies 
Technics: 




Figure 2. FISH with Vysis LSI ETV6 break apart probe 
showing a fused signal on an unaffected chromosome 12 
and split green and orange signals  
representing the abnormal chromosomes 12 and 13 
respectively (arrows) 
Results: 
A nonsense variant (.c.2693G>A) in the ASXL1 
gene was detected using the Illumina TruSight 
Myeloid Panel: Nonsense variants in ASXL1 gene 
are associated with poor prognosis (Metzeler et al, 
2011). 
Comments 
The t(12;13)(p13;q12) is very rare in hematological 
malignancies with only 14 cases including the 
present case have been reported [Table 1].  Six cases 
were diagnosed with myeloproliferative neoplasms 
with eosinophilia (MPNeo), five had AML, and the 
remaining three were pediatric ALL [see Table1 for 
references].   
 
Acute myeloid leukemia with t(12;13)(p13;q12) and ETV6 
involvement; Case report and review of literature. 





Atlas Genet Cytogenet Oncol Haematol. 2019; 23(8) 251 
 
Molecular characterization of the t(12;13) 
breakpoints revealed the rearrangement of 
ETV6/12p13 gene in 9/14 cases. On the other hand, 
FLT3 gene was implicated as the involved partner 
gene on chromosome 13 in five cases. All five were 
diagnosed with MPNeo, nevertheless the disease 
was rapidly fatal in three patients [Table 1]. FTL3 
encodes a member of the receptor tyrosine kinase 
subclass III family of receptors, which is expressed 
in early hematopoietic progenitor cells (Gilliland & 
Griffin, 2002; Stirewalt & Radich 2003). Mutations 
in FTL3 gene are found in approximately 30% of 
AML cases, yet this gene is rarely involved in 
translocations. Vu et al reported the first case of 
t(12;13)(p13;q12) in MPNeo, with the translocation 
resulting in the creation of an ETV6-FLT3 fusion 
gene. Reciprocal ETV6/FLT3 and FLT3/ETV6 
transcripts were detected by RT-PCR; however, at 
the protein level, only ETV6/FLT3 was expressed in 
the patient's leukemic cells (Vu et al, 2006). The 
putative oncogenic function gained as a result of the 
ETV6-FLT3 fusion is the constitutive activation of 
the tyrosine kinase domains of FLT3.  One case of 
t(12;13)(p13;q12)-related AML involving a ETV6-
CDX2 fusion has been described as well (Chase et 
al, 1999). Although FISH results in the present case 
revealed the involvement of ETV6 gene in the 
t(12;13) translocation, it is unknown whether a 
specific gene may have been affect at the 13q12 
locus.  
Unlike FLT3 gene, ETV6/12p13 translocations is 
commonly detected in a wide spectrum of 
hematological malignancies lymphoid and myeloid; 
with at least 48 chromosomal bands and 30 ETV6 
partner genes have been reported.  The chimeric 
oncoprotein resulted from the t(12;13) may have a 
therapeutic implications. Although the ETV6-FLT3 
positive leukemia has shown some sensitivity to 
FLT3 inhibitors, more cases are needed to appreciate 
the response.  
 




1 68Y/F MPN-eo ETV6-FLT3 Deceased 21 Vu et al.,  2006 
2 40Y/F MPN-eo ETV6-FLT3 Alive - CR 11 Falchi et al.,  2014 
3 60Y/M MPN-eo ETV6-FLT3 Deceased 7 Walz et al.,  2011 
4 49Y/M MPN-eo NR Deceased 11 Chiyoda et al.,  1994 
5 29Y/M MPN-eo ETV6-FLT3 Deceased 13 Walz et al., 2011 
6 33Y/M T-ALL and MPN-eo ETV6-FLT3 Alive - CR 72 Chonabayashi, et al., 2013 
7 5Y/M ALL NR Alive - CR 24 Keene, 1987 
8 9Y ALL NR Alive - CR NR Heerema et al., 2000 
9 17Y/F ALL ETV6-? Deceased 29 Wlodarska et al., 1987 
10 62Y/F MDS-RAEB NR NR NR Knapp et al., 1985 
11 51Y/M AML-M0 ETV6-? NR NR Tosi et al., 1998 
12 40Y/M Therapy-related AML NR Deceased 1 Clavio et al., 2001 
13 66Y/M AML ETV6-CDX2 Deceased 40 Chase, 1999 
14 61Y/M AML ETV6-? Alive 3 Present case 2018 
Table 1; Clinical data on patients reported with t(12;13)(p13;q12).
ALL: F; female: M; male; acute lymphoblastic leukemia; AML: acute myeloid leukemia; CR: complete remission; MDS-RAEB: 
myelodysplastic syndrome with refractory anemia and excess blasts; MPN-eo: myeloproliferative neoplasms with eosinophilia; 
NR: not reported; PTCL: peripheral T-cell lymphoma; Y: years 
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